ASX Announcement

31 July 2026

Tissue Repair ("TRP") JUNE 2026 APPENDIX 4C

31 July 2026 - Tissue Repair Limited (ASX:TRP, TRP or the Company) is pleased to update the market on its progress in the June 2026 quarter and attaches its Appendix 4C Quarterly Cashflow Report for the period.

Key Highlights and Update

- US Phase III chronic wound trial approaching major milestone, with approximately 100 patients randomised and recruitment continuing.
- 510(k) medical device submission remains on track for October 2026, with European CE Mark Class II submission to follow.
- Favourable US reimbursement framework established following April 2026 regulatory changes, indicating potential reimbursement of approximately US$1,270 per 10g tube in wound clinic settings.
- TR Pro+ Australian commercial launch progressing, with first GMP production completed and three product formats (10g, 30g and 200g) to be released shortly.
- Manufacturing scale-up costs materially reduced, with a second-hand centrifuge expected to accelerate pilot API production while avoiding significant capital expenditure.
- Strong cash position of $4.76 million at quarter end, supplemented by receipt of a $1.9 million R&D Tax for FY25 Incentive refund on 1 July 2026. The estimated R&D Tax for FY26 Incentive refund is $2.2 million.
- The cash balance at 1 July 2026 equals $6.66 million.

Operational Update

TR-987 – Chronic Wounds

The Company's US Phase III clinical trial continues to progress well, with approximately 100 patients now randomised. Patient recruitment remains ongoing, with recent recruitment rates averaging around 10 new randomisations per month.

TRP remains on schedule to submit a US FDA 510(k) medical device application during October 2026, followed shortly thereafter by a European CE Mark Class II submission.

Importantly, recent regulatory reimbursement changes implemented in April 2026 have significantly strengthened the commercial opportunity for a device pathway. Preliminary reimbursement analysis indicates that treatment of a 10cm² chronic wound could attract reimbursement of approximately US$1,270 per 10g tube, with approximately 60% expected to be retained by the product supplier, providing the potential for attractive commercial margins.

While reimbursement outcomes will ultimately depend on payer adoption following regulatory approval, these developments substantially enhance the commercial potential of TR-987.

TR Pro+ – Global Acute and Aesthetic Wound Opportunity

Following regulatory approval as a medical device, TRP intends to pursue the substantially larger global acute wound market.

The proposed strategy includes commercialisation of TR-987 across:

- Acute wounds
- Minor surgical wounds
- Hard-to-heal wounds
- Dermatological applications
- Everyday consumer wounds including cuts, grazes and mild burns

The Company also sees the opportunity to introduce a separately branded active wound repair product through pharmacy channels globally.

In Australia, TRP has successfully completed its first commercial GMP production run of TR Pro+ as a TGA-listed medicine. Product availability in 10g, 30g and 200g pack sizes is expected shortly.

The initial production schedule was delayed as the Company's GMP manufacturing partner completed validation requirements associated with the first commercial manufacturing run.

Sales through Advanced Cosmeceuticals currently remain below 3,000 tubes per month, broadly consistent with sales levels achieved by the Company's internal sales team prior to the distribution transition in September 2025.

Strategic Milestones

Set out below are the key strategic milestones of the business:

Initiative	Current Status	Target Timing
US Reimbursement	Independent regulatory review completed. Preliminary assessment indicates reimbursement of approximately US$127 per cm² in wound clinic settings, equating to approximately US$1,270 per 10g tube for a 10cm² wound.	Ongoing following regulatory approval.
FDA 510(k) & CE Mark	Testing and dossier preparation progressing. Submission targeted for early October 2026.	Submission October 2026. Estimated approval within 6–12 months.
Phase III Clinical Trial	Approximately 100 patients randomised. Recruitment continuing.	Ongoing.

Initiative	Current Status	Target Timing
CMC Manufacturing Scale-up	Scale-up manufacturing partner secured. Low-cost centrifuge solution expected to materially reduce capital expenditure while accelerating pilot production.	Equipment expected within one month. Pilot production targeted within three months.
Australian Commercialisation	Brand strategy and positioning program commenced with external branding agency.	Ongoing.
Scientific Publications	Publication secured describing TR-987 mechanism of action: *Beta Glucan – A Macrophage Differentiation Modulator that Accelerates the Wound Healing Response*.	Published.
Medical Advisory Board	Draft charter completed. Key Opinion Leaders being approached. Dr Steven Liew has agreed to chair the Board.	September 2026 commencement.

Corporate and Financial Summary

The Company's cash position as at 30 June 2026 was $4.759 million. During the June 2026 quarter, the Company recorded net operating cash outflows of $1.848 million, reflecting continued investment in research and development and core operational activities.

Operating cash outflows were primarily attributable to research and development expenditure of $1.09 million, product manufacturing and operating costs of $308k, staff costs of $296k, advertising and marketing of $131k and administration and corporate costs of $249k. These outflows were partially offset by customer receipts of $144k and interest income of $82k.

The Company continues to actively manage its cash position while progressing its development and commercialisation activities. The company received its FY25 R&D refund of $1.9 million on 1 July 2026, after the reporting period.

A summary of operating cash flows for the period ended 30 June 2026, compared with the intended use of funds outlined in the Company's Prospectus dated 7 October 2021, is provided below:

	Use of Funds under Prospectus	**Actual use of funds for the period ending 30 June 2026**
Working capital and overheads[1]	300,000[1]	6,557,000[1]
Offer costs	2,300,000	1,849,000
Development of Chronic Wound Drug	3,700,000	12,506,000
Phase III Clinical Trials	13,600,000	5,571,000
Commercialisation of Aesthetic Product	2,100,000	4,403,000
Interest received	-	(1,719,000)

R&D tax incentive refund	-	(2,861,000)
TR Pro+ ™ Sales receipts	-	(1,146,000)
Total	**22,000,000**	**25,160,000**

[1]The Company raised $7.5million via a convertible note in April 2021 (pre-IPO) which has been allocated to fund a significant portion of the working capital and overheads of the Company. The working capital and overhead cash outflows are broadly in line with the forecast budget. The Company believes the working capital outflows are consistent with the requirements for an ASX listed biotech Company of its size.

In Accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C was $73,000. This includes payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates including superannuation, excluding reimbursements of out-of-pocket expenses.

This announcement has been approved for release by TRP's board

--ENDS-

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Tissue Repair Limited	
ABN	**Quarter ended ("current quarter")**
20 158 411 566	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	144	640
1.2	Payments for		
	(a) research and development	(1,090)	(4,129)
	(b) product manufacturing and operating costs	(308)	(1,422)
	(c) advertising and marketing	(131)	(268)
	(d) leased assets	-	-
	(e) staff costs	(296)	(1,257)
	(f) administration and corporate costs	(249)	(1,249)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	82	237
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(1,848)**	**(7,448)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(24)	(44)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(24)**	**(44)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**-**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	6,657	12,318
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,848)	(7,448)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(24)	(44)

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(26)	(68)
4.6	**Cash and cash equivalents at end of period**	**4,759**	**4,759**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,676	2,200
5.2	Call deposits	3,083	4,457
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,759**	**6,657**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	73
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees (including superannuation) for directors, Executive Director fees and related parties.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,848)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,759
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,759
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**2.6**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

31 July 2026

Date: .....

The Board

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.